8-K: Bausch + Lomb Raises Full-Year Guidance on Strong Q2 Revenue Growth

Bausch + Lomb Corporation reported second-quarter 2025 revenue of $1.278 billion, a 5% increase, and raised its full-year 2025 financial guidance, reflecting solid business performance and foreign exchange impacts, even as it posted a GAAP net loss.

Summary

• Q2 2025 revenue reached $1.278 billion, a 5% increase as reported and 3% on a constant currency basis compared to Q2 2024.
• GAAP Net Loss Attributable to Bausch + Lomb Corporation was $62 million, a favorable change of $89 million compared to a $151 million loss in Q2 2024.
• Adjusted EBITDA (non-GAAP) was $191 million, a decrease of $18 million from $209 million in Q2 2024.
• Operating loss was $11 million, a decrease of $37 million from operating income of $26 million in Q2 2024, primarily due to higher selling and advertising costs for MIEBO and a one-time impact from the enVista IOL recall.
• Cash flow from operations increased by $20 million to $35 million, driven by improved working capital, partially offset by refinancing fees.
• Full-year 2025 revenue guidance was raised to $5.050 billion $5.150 billion (from $5.000 billion $5.100 billion), with constant currency growth expected at 5-7%.
• Full-year Adjusted EBITDA Excluding Acquired IPR&D guidance was raised to $860 million $910 million (from $850 million $900 million).

Sentiment

Score: 7

Explanation: The company demonstrated robust top-line growth and significantly narrowed its GAAP net loss. The decision to raise full-year guidance for both revenue and Adjusted EBITDA indicates confidence in future performance. While operating income declined and Adjusted EBITDA decreased, these were attributed to specific factors like increased marketing spend for new products and the one-time impact of a product recall, which has since seen production resumed. The successful debt refinancing also strengthens the balance sheet. The overall outlook is positive despite some operational headwinds.

Positives

• Total reported revenue increased by 5% to $1.278 billion in Q2 2025 compared to Q2 2024.
• Revenue grew 3% on a constant currency basis, absorbing the enVista Intraocular Lenses voluntary recall impact.
• Full-year 2025 guidance for revenue and Adjusted EBITDA was raised, reflecting strong business performance and favorable foreign exchange.
• GAAP Net Loss significantly narrowed to $62 million in Q2 2025 from $151 million in Q2 2024.
• Cash flow from operations increased by $20 million to $35 million, primarily due to improvement in working capital.
• Resumed full production of all enVista platform IOLs following their return to market.
• Dry eye portfolio reached approximately $1 billion in trailing 12-month revenue.
• Vision Care segment revenue grew 8% reported and 6% constant currency, driven by key contact lens franchises (Daily SiHy, ULTRA monthly, Biotrue ONEday) and strong consumer brands (ARTELAC, LUMIFY, Blink).
• Successfully executed a refinancing transaction, extending the maturity profile of debt.

Negatives

• GAAP Operating loss of $11 million in Q2 2025, a decrease of $37 million from operating income of $26 million in Q2 2024.
• Adjusted EBITDA (non-GAAP) decreased by $18 million to $191 million in Q2 2025 compared to Q2 2024.
• Pharmaceuticals segment revenue decreased by $1 million (1% constant currency) due to a decline in the U.S. Generics business and gross-to-net pricing pressure, primarily from XIIDRA.
• Operating results were negatively impacted by higher selling and advertising and promotion costs, primarily attributable to MIEBO.
• The voluntary recall of certain enVista IOL products had a one-time impact on operating results.
• Adjusted net income attributable to Bausch + Lomb Corporation decreased by $20 million to $25 million in Q2 2025 compared to Q2 2024.

Risks

• Uncertainties regarding the proposed plan to separate Bausch + Lomb into an independent, publicly traded company from Bausch Health Companies Inc. (BHC), including expected benefits, costs, timing, and terms.
• Potential for the separation to not occur at all, or not on anticipated terms/timelines, or in the manner anticipated.
• Risks related to the completion of the separation, including achieving targeted debt leverage ratios, receipt of shareholder and other necessary approvals, and market conditions.
• Impact of any potential sales or dispositions of Bausch + Lomb common shares by BHC, including in connection with a foreclosure on shares pledged as collateral for BHC's debt.
• Business disruption during or following the separation, diversion of management time, and challenges in retaining existing management team members.
• Reactions of customers and other parties to the separation.
• Uncertainty regarding the qualification of the distribution as a tax-free transaction for Canadian and/or U.S. federal income tax purposes, and the ability to maintain such tax-free status.
• Potential dis-synergy costs resulting from the separation.
• Impact of the separation on relationships with customers, suppliers, employees, and other business counterparties.
• Risks associated with acquisitions (e.g., XIIDRA, Elios Vision, Trukera Medical, Whitecap Biosciences), including not realizing expected benefits, increased debt levels, and compliance with debt covenants.
• Risks related to the voluntary recall of enVista IOL products, specifically the ability to resupply inventory to the market and the success of enhanced protocols for inspection and third-party suppliers.
• Expected impact of tariffs imposed by the U.S. and counter-tariffs or retaliatory measures by other countries, and disruptions to global supply chains.
• Adverse economic conditions and other macroeconomic factors, including heightened inflation, interest rates, fluctuations in exchange rates, imposition of tariffs, slower growth, or a potential recession, which could negatively impact revenue, expenses, and margins.

Future Outlook

Bausch + Lomb raised its full-year 2025 guidance, now expecting total revenue between $5.050 billion and $5.150 billion, representing approximately 5% to 7% constant currency growth. The company also increased its full-year Adjusted EBITDA Excluding Acquired IPR&D guidance to a range of $860 million to $910 million. These upward revisions are attributed to solid business performance and an increase in expected currency tailwinds.

Management Comments

• Our continued growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions around the world.
• Our robust pipeline represents the future of the company, and we're excited to showcase potential gamechangers at our November 13 investor day.

Industry Context

Bausch + Lomb's performance reflects a dynamic eye health market, where innovation in contact lenses, dry eye treatments, and surgical devices drives growth. The company's ability to resume full production of enVista IOLs and achieve significant revenue in its dry eye portfolio positions it well within the competitive landscape. The slight decline in U.S. Generics and pricing pressure on XIIDRA highlight challenges common in the pharmaceutical segment, while strong performance in consumer eye care and contact lenses aligns with broader trends of increasing demand for vision correction and eye health solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. However, the company's focus on 'hero products' and 'new introductions' suggests a strategy aligned with industry leaders who prioritize R&D and portfolio diversification to maintain competitive advantage in the eye health sector.

Stakeholder Impact

• Shareholders: Positive impact from raised guidance, strong revenue growth, and narrowed net loss, potentially leading to increased share price. Risks related to the BHC separation and potential share dispositions could introduce volatility.
• Customers: Positive impact from resumed full production of enVista IOLs and continued introduction of new products, enhancing product availability and choice.
• Employees: Potential for business disruption and retention challenges related to the proposed separation from BHC.
• Creditors: Positive impact from successful debt refinancing, extending maturity profile.

Next Steps

• Showcase potential gamechangers at the November 13 investor day.
• Continue to manage the expected impact of tariffs and counter-tariffs.
• Continue to manage adjusted SG&A expense.

Key Dates

Recommendation

The company demonstrated robust top-line growth with a 5% increase in reported revenue and a 3% constant currency growth, which is commendable given the absorption of the enVista IOL recall impact. The significant narrowing of the GAAP net loss and the positive shift in cash flow from operations indicate improving financial health. Most importantly, management raised its full-year guidance for both revenue and Adjusted EBITDA, signaling strong confidence in continued business performance and favorable market conditions. The successful refinancing transaction also strengthens the company's financial structure. While there was a decline in operating income and Adjusted EBITDA, these were attributed to strategic investments in new products (MIEBO) and one-time recall impacts, which are manageable. The resumption of full enVista IOL production and the achievement of $1 billion in dry eye portfolio revenue highlight successful operational execution and strong product demand. The upcoming investor day also suggests a robust pipeline. These factors collectively point to a positive trajectory for the company, making it an attractive 'buy' for investors looking for growth in the eye health sector.

Keywords

Eye Health, Ophthalmology, Contact Lenses, Intraocular Lenses, Pharmaceuticals, Medical Devices, Vision Care, Dry Eye, SEC Filing, Earnings Report, Financial Results, BLCO, Bausch + Lomb